MichaelYoon-SukChoiMD

Gastroenterology • Boston, MA

Assistant Professor, Medicine, Massachusetts General Hospital, Harvard Medical School

Join to view full profile

Dr. Choi is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Choi's full profile

Already have an account?

Office
55 Fruit Street Blk 4
Gastroenterology Associates
Boston, MA 02114
Phone(617) 724-6006
Fax(617) 724-6832
Is this information wrong?

Education & Training

Dana - Farber Cancer InstitutePost-Doctoral Fellowship, 2003 - 2008
Massachusetts General HospitalFellowship, Gastroenterology, 2000 - 2005
UCSFResidency, Internal Medicine, 1997 - 2000
Weill Cornell Medical College of Cornell UniversityClass of 1997

Certifications & Licensure

MA State Medical License 2003 - 2022
ME State Medical License Active through 2021
American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Publications & Presentations

PubMed

MicroRNAs Are Indispensable for Reprogramming Mouse Embryonic Fibroblasts into Induced Stem Cell-Like Cells.
Kim, B. M., Thier, M. C., Oh, S., Sherwood, R., Kanellopoulou, C., Edenhofer, F., Choi, M. Y.> ;PLoS ONE. 2012

Lectures

A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ibrutinib Reduces Obinutuzumab-Gazyva Infusion Related Reactions (IRR) in Patients with Chronic Lymphocytic Leukemia (CLL) and It Is Associated with Changes on Plasma ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Enzyme Treatment Reduces Alcohol-Induced Liver Damage in Mouse ModelsApril 25th, 2017